First Non-Hormonal Hot Flash Drugs Could Clear FDA Panel In March
This article was originally published in The Pink Sheet Daily
Executive Summary
Depomed’s gabapentin and Noven Pharmaceuticals’ paroxetine to get advisory committee review for a menopausal hot flash indication; while Phase III data for both drugs are positive, certain endpoints did not reach statistical significance in at least one study.